PP2A Cancerous-IN-1

PP2A Cancerous-IN-1 is a strong and potent CIP2A (Cancerous inhibitor of PP2A) and p-Akt inhibitor. PP2A Cancerous-IN-1 shows the most potent antiproliferative activities[1].

Research Areas >> Cancer

Signaling Pathways >> PI3K/Akt/mTOR >> Akt

pAKT

PP2A Cancerous-IN-1 (2.5 and 5 μM; 24 hours; SK-Hep-1 cells) reduces CIP2A expression and cell viability with a dose dependent manner and is more potent in its action than erlotinib[1]. PP2A Cancerous-IN-1 (5 μM; 24 hours; SK-Hep-1 cells) induces cell apoptosis[1]. PP2A Cancerous-IN-1 shows CIP2A inhibitory activity, reduces p-Akt level, induces PARP cleavage. PP2A Cancerous-IN-1 exhibits high potency with low IC50 values of 2.8 μM against HCC cells[1]. Cell Viability Assay[1] Cell Line: SK-Hep-1 cells Concentration: 2.5 and 5 μM Incubation Time: 24 hours Result: Reduced cell viability with a dose dependent manner. Western Blot Analysis[1] Cell Line: SK-Hep-1 cells Concentration: 2.5 and 5 μM Incubation Time: 24 hours Result: Reduced CIP2A expression. Apoptosis Analysis[1] Cell Line: SK-Hep-1 cells Concentration: 2.5 and 5 μM Incubation Time: 24 hours Result: Induced cell apoptosis.

[1]. Chen KF, et al. Development of erlotinib derivatives as CIP2A-ablating agents independent of EGFR activity. Bioorg Med Chem. 2012;20(20):6144-6153.